Nishimura H, Imamura K, Chang C
Dept. of Obstetrics & Gynecology, Kurume University Medical Center, Japan.
Gan To Kagaku Ryoho. 1996 Aug;23(9):1124-8.
The standard treatment for ovarian cancer is cytoreductive surgery followed by platinum-based combination chemotherapy. Although high response rates of this treatment are reported, 40-60% of patients achieving a complete response may relapse. Therefore, second-line chemotherapy is required. Second-line chemotherapy of patients with recurrent ovarian cancer should be based on their sensitivity to first-line chemotherapy and the platina-free interval. Patients who respond to the platina-based chemotherapy still may be sensitive to further platina-based chemotherapy. Patients who do not respond to the platina-based chemotherapy or who have relapses shortly after first-line chemotherapy should be considered clinically resistant to further platina-based chemotherapy. For such patients the chemotherapy regimen should be changed. These regimens include paclitaxel and hexamethylmelamine. The effect of intraperitoneal chemotherapy may depend on the size of the largest residual tumor nodule and the patient's sensitivity to previous chemotherapy.
卵巢癌的标准治疗方法是肿瘤细胞减灭术，随后进行铂类联合化疗。尽管该治疗方法有较高的缓解率报道，但40%-60%达到完全缓解的患者可能会复发。因此，需要进行二线化疗。复发性卵巢癌患者的二线化疗应基于其对一线化疗的敏感性和无铂间期。对铂类化疗有反应的患者可能仍对进一步的铂类化疗敏感。对铂类化疗无反应或在一线化疗后不久复发的患者应被视为临床上对进一步铂类化疗耐药。对于此类患者，化疗方案应改变。这些方案包括紫杉醇和六甲蜜胺。腹腔化疗的效果可能取决于最大残留肿瘤结节的大小以及患者对先前化疗的敏感性。
